Who Paid My Doc
Paul Martin
Hepatology West Hollywood, CA Medical Doctor
NPI 1184642910 CMS profile 7731
8900 Beverly Blvd Fl 3, West Hollywood, CA 90048
General payments
$39,421
Research payments
$7,878
Ownership & investment interest
$0
Research they led as principal investigator
$209,979
Through program year 2025, Paul Martin of West Hollywood, CA is reported in the CMS Open Payments database as having received $39,421 across 38 general payments and $7,878 in research payments paid to them. Separately, studies naming them as principal investigator received $209,979 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 76th percentile of Hepatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,626 | 3 | |
| 2025 | Research | $748 | 1 | |
| 2024 | General | $20 | 1 | |
| 2024 | Research | $6,380 | 3 | |
| 2023 | General | $6,183 | 4 | |
| 2022 | Research | $750 | 1 | |
| 2021 | General | $4,400 | 3 | |
| 2020 | General | $9,700 | 4 | |
| 2019 | General | $16,492 | 23 |
Beside peers
- Paul Martin
- Hepatology median
- Middle half of Hepatology
- National median
In program year 2025, general payments to Paul Martin were reported at $2,626. Among 186 Hepatology profiles paid that year, the median was $937 and the middle half received between $213 and $19,932.
Show as a table
| Year | Paul Martin | Hepatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $16,492 | $1,151 | $155–$15,665 | $163 |
| 2020 | $9,700 | $1,450 | $116–$10,568 | $114 |
| 2021 | $4,400 | $1,165 | $89–$8,210 | $132 |
| 2022 | $0 | $546 | $125–$14,024 | $149 |
| 2023 | $6,183 | $417 | $118–$7,955 | $160 |
| 2024 | $20 | $619 | $148–$16,504 | $164 |
| 2025 | $2,626 | $937 | $213–$19,932 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
472
Drug cost
$265,755
Branded share of claims
46%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ocaliva Obeticholic Acid | Brand | 12 | $114,767 | |
| Xifaxan Rifaximin | Brand | 22 | $75,982 | |
| Vemlidy Tenofovir Alafenamide | Brand | 26 | $45,207 | |
| Ursodiol | Generic | 56 | $15,050 | |
| Entecavir | Generic | 13 | $5,461 | |
| Tacrolimus | Generic | 12 | $2,797 | |
| Mycophenolate Mofetil | Generic | 14 | $1,403 | |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | Brand | 90 | $1,129 | |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | Brand | 13 | $733 | |
| Pantoprazole Sodium | Generic | 54 | $660 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$41,243
Medicare patients
260
Services billed
418
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 55% | |
| Diabetes | 41% | |
| Ischemic heart disease | 31% | |
| Chronic kidney disease | 31% | |
| Depression | 27% | |
| Osteoporosis | 22% | |
| COPD | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
43 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hepatology in California
Related records
Hepatology in California
Practitioners in the same specialty and state, ranked by reported value.
All Hepatology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.